Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
allergan
15
×
life sciences
15
×
national blog main
biotech
boston blog main
clinical trials
national top stories
boston top stories
new york blog main
texas blog main
texas top stories
fda
san diego blog main
san diego top stories
san francisco blog main
eli lilly
national
new york top stories
raleigh-durham blog main
san francisco top stories
abbvie
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham top stories
seattle blog main
seattle top stories
wisconsin blog main
wisconsin top stories
botox
bristol-myers squibb
ipo
medical device
medical devices
acquisition
amgen
buyout
What
bio
fda
medicines
roundup
acelity
antonio
drug
drugs
known
medicine
new
san
treatment
won
allergan
approved
biotech
black
ceo
class
companies
company
days
deal
decades
diamond’s
editas
editing
experimental
gene
ipo
life
migraine
notes
plans
products
regulatory
science
sciences
therapeutics
Language
unset
Current search:
allergan
×
" life sciences "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Acelity Sells to 3M in Deal Valued at $6.7 Billion, Ending IPO Plan
@xconomy.com
5 years ago
San Antonio Wound-Care Company Eyes (Another) Initial Public Offering
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
San Antonio Life Science Business Acelity Cuts 260 Jobs in Texas, NC
@xconomy.com
5 years ago
Former Zavante Executive Tapped as Abide Therapeutics President
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More